1Bz-LSD

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

1Bz-LSD, also known as 1-benzoyl-LSD or as SYN-L-018, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is thought to be a prodrug of LSD. The drug was patented by Lizard Labs in 2024.

Subsequently, it was encountered online as a novel designer drug in July 2024. 1Bz-LSD has been sold in the form of blotter tabs and microdots, for instance containing 10 μg and 200 μg doses per unit. A deethylated metabolite, 1Bz-LAE, has been identified.

1Bz-LSD was first described in the scientific literature by 2026. It is not an explicitly controlled substance in the United States or in Canada.

1Bz-LSD, also known as 1-benzoyl-LSD or as SYN-L-018, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is thought to be a prodrug of LSD. The drug was patented by Lizard Labs in 2024.

Subsequently, it was encountered online as a novel designer drug in July 2024. 1Bz-LSD has been sold in the form of blotter tabs and microdots, for instance containing 10 μg and 200 μg doses per unit. A deethylated metabolite, 1Bz-LAE, has been identified.

1Bz-LSD was first described in the scientific literature by 2026. It is not an explicitly controlled substance in the United States or in Canada.

See also

Substituted lysergamide 1SB-LSD 1-Benzoyl-DMT

New lysergamide 1bz-LSD - r/researchchemicals - Reddit

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368190931 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.